Results 91 to 100 of about 8,424 (263)

Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. [PDF]

PLoS ONE, 2014
The mainstay of treatment for thrombosis, the formation of occlusive platelet aggregates that often lead to heart attack and stroke, is antiplatelet therapy. Antiplatelet therapy dosing and resistance are poorly understood, leading to potential incorrect
Melissa Li, Nathan A Hotaling, David N Ku, Craig R Forest   +3 more
doaj   +1 more source

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Archiv der Pharmazie, Volume 357, Issue 11, November 2024.
Sickle cell disease reflects a complex interplay of genetics, hematology, and clinical symptoms. The intricate pathogenesis of the disease offers a landscape with various targets and treatment options. Anticipated advancements in treatment include combining fetal hemoglobin inducers with other drug classes to improve the efficacy beyond monotherapy ...
Chandu Ala, Renuka Parshuram Joshi, Pragya Gupta, Sangam Giri Goswami, Sivaprakash Ramalingam, Chandra Sekhar Kondapalli Venkata Gowri, Murugesan Sankaranarayanan   +6 more
wiley   +1 more source

Relation of Level of Platelet Inhibition after Eptifibatide with Major Cardiovascular Events in ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Majalah Kardiologi Indonesia, 2015
Background: Eptifibatide, an inhibitor of glycoprotein IIb/IIIa administered as adjunctive therapy to reperfusion therapy Primary PCI in STEMI patients.
Elisa Feriyanti Pakpahan, Sunarya Soerianata, Nur Haryono   +2 more
doaj   +1 more source

Overcoming thrombolytic resistance Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction [PDF]

, 1999
OBJECTIVESWe sought to review the emerging data and the clinical rationale for combining glycoprotein (GP) IIb/IIIa inhibitors with thrombolytic therapy for acute myocardial infarction (AMI).BACKGROUNDAlthough thrombolytic therapy has been a major ...
Cannon, Christopher P
core   +1 more source

FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond

Journal of Peptide Science, Volume 30, Issue 11, November 2024.
This review provides an overview of FDA‐approved peptides, particularly those targeting cardiovascular diseases, human immunodeficiency, and central nervous system diseases, and also addresses conditions such as osteoporosis, thrombocytopenia, Cushing's disease, and hypoglycemia.
Othman Al Musaimi
wiley   +1 more source

Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions

The Egyptian Heart Journal, 2014
Background: Platelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation. Aim: To compare the degree of platelet aggregation inhibition
Yasser Sadek Nassar, Mohamed Laimud, Mohamed Afify, Mohamed Ashraf Shawky   +3 more
doaj   +1 more source

Therapeutic Plasma Exchange to Reverse Plasma Failure in Multiple Organ Dysfunction Syndrome

Journal of Clinical Apheresis, Volume 39, Issue 5, October 2024.
ABSTRACT Plasma plays a crucial role in maintaining health through regulating coagulation and inflammation. Both are essential to respond to homeostatic threats such as traumatic injury or microbial infection; however, left unchecked, they can themselves cause damage.
Matthew J. Foglia, Jay S. Raval, Jan C. Hofmann, Joseph A. Carcillo   +3 more
wiley   +1 more source

Mechanisms of Xenogeneic Baboon Platelet Aggregation and Phagocytosis by Porcine Liver Sinusoidal Endothelial Cells [PDF]

, 2012
Background: Baboons receiving xenogeneic livers from wild type and transgenic pigs survive less than 10 days. One of the major issues is the early development of profound thrombocytopenia that results in fatal hemorrhage.
Buhler, Leo, Csizmad, Eva, Deng, Shaoping, Enjyoj, Keiichi, Lee, Kang Mi, Machaidze, Zurab, Markmann, James, Peng, Qiang, Robson, Simon Christopher, Schuetz, Christian, Wei, Lingling, Yeh, Heidi   +11 more
core   +3 more sources

Anoikis in cell fate, physiopathology, and therapeutic interventions

MedComm, Volume 5, Issue 10, October 2024.
1. Anoikis is an integrin‐dependent form of apoptosis and can affect cell fate. 2. Anoikis widely exists in the physiological and pathological processes of life. 3. Anoikis‐based regulatory strategies are potential targets for therapeutic intervention.
Jie Mei, Xue‐Yao Jiang, Hui‐Xiang Tian, Ding‐Chao Rong, Jia‐Nan Song, Luozixian Wang, Yuan‐Shen Chen, Raymond C. B. Wong, Cheng‐Xian Guo, Lian‐Sheng Wang, Lei‐Yun Wang, Peng‐Yuan Wang, Ji‐Ye Yin   +12 more
wiley   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj